[go: up one dir, main page]

SI2003120T1 - Azapeptidni derivati kot inhibitorji hiv proteaze - Google Patents

Azapeptidni derivati kot inhibitorji hiv proteaze

Info

Publication number
SI2003120T1
SI2003120T1 SI200830012T SI200830012T SI2003120T1 SI 2003120 T1 SI2003120 T1 SI 2003120T1 SI 200830012 T SI200830012 T SI 200830012T SI 200830012 T SI200830012 T SI 200830012T SI 2003120 T1 SI2003120 T1 SI 2003120T1
Authority
SI
Slovenia
Prior art keywords
protease inhibitors
hiv protease
azapeptide derivatives
azapeptide
derivatives
Prior art date
Application number
SI200830012T
Other languages
English (en)
Inventor
Scott L Harbeson
Roger D Tung
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of SI2003120T1 publication Critical patent/SI2003120T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
SI200830012T 2007-06-12 2008-06-12 Azapeptidni derivati kot inhibitorji hiv proteaze SI2003120T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93420107P 2007-06-12 2007-06-12
US6762708P 2008-02-29 2008-02-29
EP08252023A EP2003120B9 (en) 2007-06-12 2008-06-12 Azapeptide derivatives as HIV protease inhibitors

Publications (1)

Publication Number Publication Date
SI2003120T1 true SI2003120T1 (sl) 2010-03-31

Family

ID=39730784

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830012T SI2003120T1 (sl) 2007-06-12 2008-06-12 Azapeptidni derivati kot inhibitorji hiv proteaze

Country Status (25)

Country Link
US (4) US20090036357A1 (sl)
EP (3) EP2322509B1 (sl)
JP (1) JP2010529196A (sl)
KR (2) KR101185899B1 (sl)
CN (2) CN102424668A (sl)
AR (1) AR066972A1 (sl)
AT (2) ATE447554T1 (sl)
AU (1) AU2008267048C1 (sl)
BR (2) BRPI0823520A2 (sl)
CA (1) CA2692028C (sl)
CO (1) CO6241121A2 (sl)
CY (1) CY1109766T1 (sl)
DE (1) DE602008000255D1 (sl)
DK (1) DK2003120T3 (sl)
ES (3) ES2395137T3 (sl)
HR (1) HRP20100065T1 (sl)
MX (1) MX2009013565A (sl)
PL (1) PL2003120T3 (sl)
PT (1) PT2003120E (sl)
RS (1) RS51226B (sl)
RU (2) RU2448958C2 (sl)
SI (1) SI2003120T1 (sl)
TW (1) TW200908970A (sl)
WO (1) WO2008156632A1 (sl)
ZA (1) ZA200909079B (sl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200835693A (en) * 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
CN102424668A (zh) 2007-06-12 2012-04-25 康塞特制药公司 氮杂肽衍生物
EP2334318B1 (en) * 2008-10-06 2016-02-10 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
WO2010135424A1 (en) * 2009-05-19 2010-11-25 Glaxosmithkline Llc Chemical compounds
CA2784530C (en) * 2009-12-21 2018-05-22 Janssen R&D Ireland Degradable removable implant for the sustained release of an active compound
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
WO2012176066A1 (en) 2011-06-20 2012-12-27 H. Lundbeck A/S Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
CN106543073A (zh) * 2015-09-17 2017-03-29 宁波杰尔盛化工有限公司 2-[4-（2-吡啶基）苄基]-肼羧酸叔丁酯的制备方法
AU2016361612B2 (en) * 2015-12-02 2021-07-29 Merck Sharp & Dohme Llc Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
JP7504791B2 (ja) 2017-09-27 2024-06-24 インサイト・コーポレイション Ｔａｍ阻害剤として有用なピロロトリアジン誘導体の塩
CN113164398B (zh) * 2018-06-29 2023-11-03 因赛特公司 Axl/mer抑制剂的制剂
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
IL296065A (en) 2020-03-06 2022-10-01 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CN116033916A (zh) * 2020-04-16 2023-04-28 威斯康星州医药大学股份有限公司 用于治疗气道反流的hiv蛋白酶抑制剂气雾剂型制剂
CN115583984A (zh) * 2022-01-11 2023-01-10 嘉兴安谛康生物科技有限公司 氮杂螺类化合物及其制备方法、药物组合物和用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT82580B (pt) 1985-05-15 1989-01-17 Wellcome Found Processo para a preparacao de 2',3'- didesoxinucleosidos e de composicoes farmaceuticas que os contem
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
DE674513T1 (de) 1992-12-29 1996-01-18 Abbott Lab Inhibitoren der retroviralen protease.
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
AU2959397A (en) 1996-05-31 1998-01-05 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9914821D0 (en) 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
EP1104760B1 (en) * 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
CZ20033211A3 (cs) 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
WO2003020206A2 (en) 2001-08-31 2003-03-13 Bristol-Myers Squibb Company Use of atazanavir in hiv therapy
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CA2676567A1 (en) 2003-02-21 2005-03-31 Jarrow Formulas, Inc. Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050148523A1 (en) 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
CA2571726C (en) * 2004-07-06 2013-05-21 Abbott Laboratories Prodrugs of hiv protease inhibitors
AU2005292339A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
RU2403066C2 (ru) 2004-12-03 2010-11-10 Мерк Шарп Энд Домэ Корп Применение атазанавира для улучшения фармакокинетики лекарственных средств, метаболизируемых ugt1a1
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
EP2059241A1 (en) * 2006-09-05 2009-05-20 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
CN102424668A (zh) 2007-06-12 2012-04-25 康塞特制药公司 氮杂肽衍生物
US20090076097A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
WO2010132663A1 (en) 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors

Also Published As

Publication number Publication date
AR066972A1 (es) 2009-09-23
ES2356334T3 (es) 2011-04-07
PT2003120E (pt) 2010-02-11
CN101711237A (zh) 2010-05-19
RU2448958C2 (ru) 2012-04-27
CA2692028A1 (en) 2008-12-24
BRPI0813911A2 (pt) 2012-02-22
DK2003120T3 (da) 2010-03-15
AU2008267048C1 (en) 2013-01-17
US20090036357A1 (en) 2009-02-05
CN101711237B (zh) 2013-08-07
ATE536343T1 (de) 2011-12-15
RS51226B (sr) 2010-12-31
HK1136576A1 (en) 2010-07-02
PL2003120T3 (pl) 2010-04-30
RU2012101881A (ru) 2013-07-27
WO2008156632A1 (en) 2008-12-24
US20130041156A1 (en) 2013-02-14
TW200908970A (en) 2009-03-01
CN102424668A (zh) 2012-04-25
US8158805B2 (en) 2012-04-17
BRPI0823520A2 (pt) 2013-12-17
US8258309B2 (en) 2012-09-04
ES2394952T3 (es) 2013-02-07
CO6241121A2 (es) 2011-01-20
ATE447554T1 (de) 2009-11-15
CY1109766T1 (el) 2014-09-10
HK1127345A1 (en) 2009-09-25
KR20100020033A (ko) 2010-02-19
EP2116532A1 (en) 2009-11-11
AU2008267048A1 (en) 2008-12-24
DE602008000255D1 (de) 2009-12-17
MX2009013565A (es) 2010-06-02
EP2003120B9 (en) 2010-06-02
RU2010100821A (ru) 2011-07-20
AU2008267048B2 (en) 2012-05-31
US20120165288A1 (en) 2012-06-28
EP2003120A1 (en) 2008-12-17
HRP20100065T1 (hr) 2010-03-31
KR101185899B1 (ko) 2012-09-27
KR20120029480A (ko) 2012-03-26
EP2003120B1 (en) 2009-11-04
JP2010529196A (ja) 2010-08-26
EP2322509A1 (en) 2011-05-18
US20110009355A1 (en) 2011-01-13
EP2322509B1 (en) 2012-08-22
EP2116532B1 (en) 2011-12-07
CA2692028C (en) 2013-06-04
ES2395137T3 (es) 2013-02-08
ZA200909079B (en) 2011-05-25

Similar Documents

Publication Publication Date Title
SI2003120T1 (sl) Azapeptidni derivati kot inhibitorji hiv proteaze
IL197777A0 (en) Enantiomerically pure phosphoindoles as hiv inhibitors
SI2078001T1 (sl) Derivati diazepan-acetamida kot selektivni zaviralci 11 -hsd1
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
IL183850A0 (en) Hiv protease inhibitors
EP2435037A4 (en) INHIBITORS OF HIV PROTEASE
EP1855672A4 (en) HIV PROTEASE INHIBITORS
AU2007337830A8 (en) Benzenesulfonamide derivatives as HIV protease inhibitors
ZA200804607B (en) Substituted aminophenylsulfonamide compounds as HIV protease inhibitor
EP2134336A4 (en) HIV PROTEASE INHIBITORS DERIVED FROM BENZOFURAN
EP2313426A4 (en) NEW PROTEASE INHIBITORS
ZA201102179B (en) Protease inhibitors
ZA200902172B (en) Enantiomerically pure phosphoindoles as HIV inhibitors
ZA200706305B (en) HIV protease inhibitors
GB0817425D0 (en) Protease inhibitors
ZA200804610B (en) Aminophenylsulfonamide derivatives as HIV protease inhibitor
HK1147995A (zh) 磺胺作為zap-70抑制劑
GB0712543D0 (en) Protease inhibitors
GB0700378D0 (en) Protease inhibitors
GB0712176D0 (en) Protease inhibitors
GB0705212D0 (en) Protease inhibitors
GB0705213D0 (en) Protease inhibitors
GB0700369D0 (en) Protease inhibitors
GB0712544D0 (en) Protease inhibitors
HK1154384A (en) Protease inhibitors